semaglutide cardiovascular outcomes news 2025 Effects of on risk of events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials | Cardiovascular Diabetology Semaglutide Shows Secondary Cardiovascular Prevention

Gene expression analysis in soybean in response to the causal agent of Asian soybean rust ( Phakopsora pachyrhizi Sydow) in an early growth stage

Digital platforms that show comparative pricing at the point of prescribing reduce sticker shock, increase adherence, and enhance patient trust

As GLP-1 demand grows and traditional plans fall behind, DTE access positions employers as healthcare decision-makers, aligning benefit design with measurable outcomes in workforce health, retention, and operational efficiency

This initial phase establishes tolerance and confirms the medication is working for appetite control

Nautiyal: I would like to highlight two key groups who are at a very high personal risk of heart attacks or strokes

Pharmacologic Treatment of Overweight and Obesity in Adults (MDText.com, 2021)